Burkitt's Lymphoma: Molecular Pathogenesis and Treatment, Cancer Investigation, vol.92, issue.6, pp.574-83, 2000. ,
DOI : 10.1007/BF01797862
Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte., Journal of Clinical Oncology, vol.14, issue.1, pp.240-288, 1996. ,
DOI : 10.1200/JCO.1996.14.1.240
Diff use small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to proMACE-based combination chemotherapy ,
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients, Annals of Oncology, vol.6, issue.5, pp.445-51, 1995. ,
DOI : 10.1093/oxfordjournals.annonc.a059214
Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society., Journal of Clinical Oncology, vol.4, issue.8, pp.1219-1245, 1986. ,
DOI : 10.1200/JCO.1986.4.8.1219
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children., Journal of Clinical Oncology, vol.9, issue.1, pp.123-155, 1991. ,
DOI : 10.1200/JCO.1991.9.1.123
The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia, Blood, vol.97, issue.11, pp.3370-79, 2001. ,
DOI : 10.1182/blood.V97.11.3370
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents, Blood, vol.109, pp.2736-2779, 2007. ,
of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients, Blood, vol.109, pp.2773-80, 2007. ,
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol, Annals of Oncology, vol.16, issue.12, pp.1928-1963, 2005. ,
DOI : 10.1093/annonc/mdi403
Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia, Journal of Clinical Oncology, vol.17, issue.8, pp.2461-70, 1999. ,
DOI : 10.1200/JCO.1999.17.8.2461
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen., Journal of Clinical Oncology, vol.14, issue.3, pp.925-959, 1996. ,
DOI : 10.1200/JCO.1996.14.3.925
Brief-duration high-intensity chemotherapy for patients with small-non cleaved lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251, J Clin Oncol, vol.19, pp.4014-4036, 2001. ,
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program, Haematologica, vol.98, issue.11, pp.1718-1743, 2013. ,
DOI : 10.3324/haematol.2013.086827
Low-Intensity Therapy in Adults with Burkitt's Lymphoma, New England Journal of Medicine, vol.369, issue.20, pp.1915-1940, 2013. ,
DOI : 10.1056/NEJMoa1308392
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report, British Journal of Haematology, vol.105, issue.3, pp.394-401, 2014. ,
DOI : 10.1111/bjh.13040
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-277, 2002. ,
DOI : 10.1056/NEJMoa011795
World Health Organization classifi cation of tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissues, International Agency for Research on Cancer Press, pp.181-84, 2001. ,
WHO classifi cation of tumours of haematopoietic and lymphoid tissues, International Agency for Research on Cancer, 2008. ,
Classifi cation, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults, Semin Oncol, vol.7, pp.332-371, 1980. ,
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group ,
Sample size tables for clinical studies, Oxford: Blackwell Science, p.251, 1997. ,
DOI : 10.1002/9781444300710
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study, Annals of Oncology, vol.13, issue.8, pp.1264-74, 2002. ,
DOI : 10.1093/annonc/mdf253
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia, American Journal of Hematology, vol.106, issue.1, pp.22-25, 2012. ,
DOI : 10.1002/ajh.22189
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial), Blood, vol.112, issue.6, pp.2248-60, 2008. ,
DOI : 10.1182/blood-2008-03-145128
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10??002, British Journal of Haematology, vol.29, issue.1, pp.102-113, 2014. ,
DOI : 10.1111/bjh.12736
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial, Blood, vol.124, issue.26, pp.3870-79, 2014. ,
DOI : 10.1182/blood-2014-03-563627
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia, Cancer, vol.23, issue.7, pp.1569-80, 2006. ,
DOI : 10.1002/cncr.21776
RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifi able' highly aggressive B-cell lymphoma ,
DOI : 10.1111/j.1365-2141.2011.08947.x
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis, Annals of Oncology, vol.22, issue.8, pp.1859-64, 2011. ,
DOI : 10.1093/annonc/mdq677